Business Wire

Countdown to the Finals of the ASC24 Student Supercomputer Challenge!

2.4.2024 11:37:00 EEST | Business Wire | Press release

Share

The 2024 ASC Student Supercomputer Challenge (ASC24) finals are scheduled to take place at Shanghai University from April 9 to 13, 2024. Among the over 300 teams representing universities worldwide, only 25 have progressed to the finals. Throughout the competition finals, teams will face a series of challenges including optimizing large language model (LLM) inference, tackling tasks like OpenCAEPoro and GoMars, as well as competing in high-performance benchmarks such as HPL and HPCG. Additionally, teams will engage in group competitions and tackle a mystery application. Each team will present their projects before the jury, contending for prestigious awards including the Champion, Silver Prize, e Prize, and the Highest LINPACK.

The ASC24 Student Supercomputer Challenge Finals

Date

Time

Agenda

April 9

08:00-20:00

Rule Announcement, Cluster Setup/Testing

April 10

08:00-20:00

Cluster Setup/Testing

April 11

08:00-18:00

Competition: HPL & HPCG, Group Competition, LLM

 

April 12

08:00-18:00

Competition: OpenCAEPoro, GoMars, mystery APP

14:00-17:00

The 33rd HPC Connection Workshop

April 13

08:00-12:10

Finalist Teams Presentations before the Jury

15:00-17:30

Closing and awards ceremony

ASC is committed to assisting students in addressing state-of-the-art scientific challenges through the utilization of the most advanced computing products and technologies. This endeavor aims to explore emerging research paradigms and confront the various challenges humanity faces. The focal point of the ASC24 finals will revolve around tackling cutting-edge scientific issues, such as advancing large language models (LLM), exploring Mars, and enhancing techniques for oil and gas exploitation.

The prestigious e Prize will be bestowed upon the winners of the OpenCAEPoro task, which entails simulating the seepage of multiphase fluids, such as oil, gas, and water, particularly within contexts relevant to petroleum extraction. Competitors are tasked with skillfully optimizing large-scale parallel computing processes, emphasizing enhancements in computing performance and parallel efficiency of discrete algorithms.

In the GoMars task, participating teams are challenged with optimizing parallel communication and refining computational load balancing within the dynamic framework of GoMars. GoMars represents a new generation of Mars atmosphere models. The objective is to enhance operational efficiency and achieve more precise predictions of the Martian atmosphere.

In the LLM Inference Optimization Challenge, participating teams are assigned the task of constructing and refining inference engines utilizing the widely employed open-source LLM, AquilaChat2-34B. The primary objective is to expedite inference processes by employing 4-bit or less quantization while maintaining overall accuracy.

Alongside the primary challenges, the finals will include a Group Competition aimed at fostering cross-team collaboration among students. Students will be randomly allocated to one of five groups. Each group will work collectively on the ParaSeis task, employing ParaSeis to simulate seismic wave propagation and refine the algorithm through collaborative communication. The group's performance will be evaluated based on the average score of its constituent teams, with the group achieving the highest score declared as the victor.

The finals will bring together formidable teams from renowned universities, including Peking University - the champion of the 10th ASC onsite finals, the Chinese University of Hong Kong - the champion of the 10th ASC virtual finals, University of Science and Technology of China, Huazhong University of Science and Technology, Shanghai Jiao Tong University, and Friedrich-Alexander-University Erlangen-Nuremberg.

Numerous new teams are set to join the finals, with Shanghai University, Lanzhou University, and Southern University of Science and Technology among them. Excitement surrounds the debut of teams from the National University of Cordoba, Macau University of Science and Technology, and Southwest Petroleum University, making their inaugural ASC finals appearance this year. The enthusiasm of these new contenders promises to elevate the competition, ensuring an intense battle until the very end.

About ASC

The ASC Student Supercomputer Challenge is the world's largest student supercomputer competition, sponsored and organized by the Asia Supercomputer Community with support from experts and institutions across Asia, Europe, and America. The main objectives of ASC are to encourage the exchange and training of young supercomputing talent from different countries, improve supercomputing applications and R&D capacity, boost the development of supercomputing, and promote technical and industrial innovation. The first ASC Student Supercomputer Challenge was held in 2012 and has since attracted over 10,000 undergraduates from all over the world. Learn more for ASC at http://www.asc-events.net/StudentChallenge/index.html.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media
media@asc-events.org

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye